163 related articles for article (PubMed ID: 30132519)
1. Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Hasslacher S; Schneele L; Stroh S; Langhans J; Zeiler K; Kattner P; Karpel-Massler G; Siegelin MD; Schneider M; Zhou S; Grunert M; Halatsch ME; Nonnenmacher L; Debatin KM; Westhoff MA
Int J Oncol; 2018 Nov; 53(5):1881-1896. PubMed ID: 30132519
[TBL] [Abstract][Full Text] [Related]
2. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
3. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
5. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Jones NM; Rowe MR; Shepherd PR; McConnell MJ
Int J Oncol; 2016 Jul; 49(1):207-16. PubMed ID: 27176780
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
8. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
Firat E; Niedermann G
Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
[TBL] [Abstract][Full Text] [Related]
9. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
Westhoff MA; Kandenwein JA; Karl S; Vellanki SH; Braun V; Eramo A; Antoniadis G; Debatin KM; Fulda S
Oncogene; 2009 Oct; 28(40):3586-96. PubMed ID: 19633683
[TBL] [Abstract][Full Text] [Related]
10. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
12. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
[TBL] [Abstract][Full Text] [Related]
13. The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
Ehrhardt M; Craveiro RB; Velz J; Olschewski M; Casati A; Schönberger S; Pietsch T; Dilloo D
J Cell Mol Med; 2018 Apr; 22(4):2153-2161. PubMed ID: 29377550
[TBL] [Abstract][Full Text] [Related]
14. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
17. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
18. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
19. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
Marampon F; Megiorni F; Camero S; Crescioli C; McDowell HP; Sferra R; Vetuschi A; Pompili S; Ventura L; De Felice F; Tombolini V; Dominici C; Maggio R; Festuccia C; Gravina GL
Cancer Lett; 2017 Jul; 397():1-11. PubMed ID: 28342984
[TBL] [Abstract][Full Text] [Related]
20. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
Xia S; Zhao Y; Yu S; Zhang M
Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
